Adherence to oral maintenance treatment in adolescents with inflammatory bowel disease

Journal of Pediatric Gastroenterology and Nutrition

Volumn 62, Issue 2, 2016, Pages 264-270

  Spekhorst, Lieke M ^a   Hummel, Thalia Z ^a   Benninga, Marc A ^b   Van Rheenen, Patrick F ^c   Kindermann, Angelika ^b  

^a MEDISCH SPECTRUM TWENTE   (Netherlands)

^b ACADEMIC MEDICAL CENTER   (Netherlands)

^c UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

Author keywords

Adolescents; Barriers; Inflammatory bowel disease; Medication nonadherence; Psychosocial factors

Indexed keywords

AMINOSALICYLIC ACID; AZATHIOPRINE; MERCAPTOPURINE;

ADOLESCENT; ADOLESCENT BEHAVIOR; ANXIETY; ARTICLE; COPING BEHAVIOR; DEPRESSION; FAMILY CONFLICT; HUMAN; INFLAMMATORY BOWEL DISEASE; MAINTENANCE THERAPY; MEDICATION COMPLIANCE; OUTCOME ASSESSMENT; PATIENT COMPLIANCE; PRIORITY JOURNAL; QUALITY OF LIFE; SOCIAL INTERACTION; SOCIAL PSYCHOLOGY; SYSTEMATIC REVIEW; ADAPTIVE BEHAVIOR; INFLAMMATORY BOWEL DISEASES; MENTAL STRESS; PSYCHOLOGY;

ADAPTATION, PSYCHOLOGICAL; ADOLESCENT; ANXIETY; DEPRESSION; HUMANS; INFLAMMATORY BOWEL DISEASES; MEDICATION ADHERENCE; QUALITY OF LIFE; STRESS, PSYCHOLOGICAL;

EID: 84957055236     PISSN: 02772116     EISSN: 15364801     Source Type: Journal    
DOI: 10.1097/MPG.0000000000000924     Document Type: Article

References (44)

1. Ruemmele FM, Veres G, Kolho KL, et al. Consensus guidelines of ECCO/ESPGHAN on the medical management of pediatric Crohn's disease. J Crohns Colitis 2014; 8: 1179-207.
2. Turner D, Levine A, Escher JC, et al. Management of pediatric ulcerative colitis: joint ECCO and ESPGHAN evidence-based consensus guidelines. J Pediatr Gastroenterol Nutr 2012; 55: 340-61.
3. Logan D, Zelikovsky N, Labay L, et al. The Illness Management Survey: identifying adolescents' perceptions of barriers to adherence. J Pediatr Psychol 2003; 28: 383-92.
4. Hommel KA, Denson LA, Crandall WV, et al. Behavioral functioning and treatment adherence in pediatric inflammatory bowel disease: review and recommendations for practice. Gastroenterol Hepatol (N Y) 2008; 4: 785.
5. DuRant RH. Checklist for the evaluation of research articles. J Adolesc Health 1994; 15: 4-8.
6. Sanderson S, Tatt ID, Higgins JPT. Tools for assessing quality and susceptibility to bias in observational studies in epidemiology: a systematic review and annotated bibliography. Int J Epidemiol 2007; 36: 666-76.
7. Gray WN, Denson LA, Baldassano RN, et al. Treatment adherence in adolescents with inflammatory bowel disease: the collective impact of barriers to adherence and anxiety/depressive symptoms. J Pediatr Psychol 2012; 37: 282-91.
8. Gumidyala AP, Greenley RN. Correlates of health-related quality of life in pediatric inflammatory bowel disease: a cumulative risk model approach. J Pediatr Psychol 2014; 39: 55-64.
9. Greenley RN, Stephens M, Doughty A, et al. Barriers to adherence among adolescents with inflammatory bowel disease. Inflamm Bowel Dis 2010; 16: 36-41.
10. Greenley RN, Kunz JH, Biank V, et al. Identifying youth nonadherence in clinical settings: data-based recommendations for children and adolescents with inflammatory bowel disease. Inflamm Bowel Dis 2012; 18: 1254-9.
11. Greenley RN, Karazsia B, Schurman JV, et al. Trajectories of oral medication adherence in youth with inflammatory bowel disease. Health Psychol 2015; 34: 514-21.
12. Hommel KA, Davis CM, Baldassano RN. Medication adherence and quality of life in pediatric inflammatory bowel disease. J Pediatr Psychol 2008; 33: 867-74.
13. Hommel KA, Davis CM, Baldassano RN. Objective versus subjective assessment of oral medication adherence in pediatric inflammatory bowel disease. Inflamm Bowel Dis 2009; 15: 589-93.
14. Hommel KA, Baldassano RN. Brief report: barriers to treatment adherence in pediatric inflammatory bowel disease. J Pediatr Psychol 2010; 35: 1005-10.
15. Hommel KA, Denson LA, Baldassano RN. Oral medication adherence and disease severity in pediatric inflammatory bowel disease. Eur J Gastroenterol Hepatol 2011; 23: 250-4.
16. Hommel KA, Herzer M, Ingerski LM, et al. Individually tailored treatment of medication nonadherence. J Pediatr Gastroenterol Nutr 2011; 53: 435-9.
17. Hommel KA, Hente E, Herzer M, et al. Telehealth behavioral treatment for medication nonadherence: a pilot and feasibility study. Eur J Gastroenterol Hepatol 2013; 25: 469-73.
18. Hommel KA, Hente EA, Odell S, et al. Evaluation of a group-based behavioral intervention to promote adherence in adolescents with inflammatory bowel disease. Eur J Gastroenterol Hepatol 2012; 24: 64-9.
19. Ingerski LM, Baldassano RN, Denson LA, et al. Barriers to oral medication adherence for adolescents with inflammatory bowel disease. J Pediatr Psychol 2010; 35: 683-91.
20. Janicke DM, Gray WN, Kahhan NA, et al. Brief report: the association between peer victimization, prosocial support, and treatment adherence in children and adolescents with inflammatory bowel disease. J Pediatr Psychol 2009; 34: 769-73.
21. Kamperidis N, Goodhand JR, Chowdhury FA, et al. Factors associated with nonadherence to thiopurines in adolescent and adult patients with inflammatory bowel disease. J Pediatr Gastroenterol Nutr 2012; 54: 685-9.
22. Kitney L, Turner JM, Spady D, et al. Predictors of medication adherence in pediatric inflammatory bowel disease patients at the Stollery Children's Hospital. Can J Gastroenterol 2009; 23: 811-5.
23. LeLeiko NS, Lobato D, Hagin S, et al. 6-Thioguanine levels in pediatric IBD patients: adherence is more important than dose. Inflamm Bowel Dis 2013; 19: 2652-8.
24. LeLeiko NS, Lobato D, Hagin S, et al. Rates and predictors of oral medication adherence in pediatric patients with IBD. Inflamm Bowel Dis 2013; 19: 832-9.
25. Mackner LM, Crandall WV. Oral medication adherence in pediatric inflammatory bowel disease. Inflamm Bowel Dis 2005; 11: 1006-12.
26. Oliva-Hemker MM, Abadom V, Cuffari C, et al. Nonadherence with thiopurine immunomodulator and mesalamine medications in children with Crohn disease. J Pediatr Gastroenterol Nutr 2007; 44: 180-4.
27. Ooi CY, Bohane TD, Lee D, et al. Thiopurine metabolite monitoring in paediatric inflammatory bowel disease. Aliment Pharmacol Ther 2007; 25: 941-7.
28. Reed-Knight B, Lewis JD, Blount RL. Behavioral functioning in youth with inflammatory bowel disease: perceived barriers as mediator of medication adherence. J Pediatr Psychol 2013; 38: 309-20.
29. Reed-Knight B, Lewis JD, Blount RL. Association of disease, adolescent, and family factors with medication adherence in pediatric inflammatory bowel disease. J Pediatr Psychol 2011; 36: 308-17.
30. Schurman JV, Cushing CC, Carpenter E, et al. Volitional and accidental nonadherence to pediatric inflammatory bowel disease treatment plans: initial investigation of associations with quality of life and disease activity. J Pediatr Psychol 2011; 36: 116-25.
31. Wu YP, Pai ALH, Gray WN, et al. Development and reliability of a correction factor for family-reported medication adherence: pediatric inflammatory bowel disease as an exemplar. J Pediatr Psychol 2013; 38: 893-901.
32. Goodhand JR, Kamperidis N, Sirwan B, et al. Factors associated with thiopurine non-adherence in patients with inflammatory bowel disease. Aliment Pharmacol Ther 2013; 38: 1097-108.
33. Hommel KA, Odell S, Sander E, et al. Treatment adherence in paediatric inflammatory bowel disease: perceptions from adolescent patients and their families. Health Soc Care Community 2011; 19: 80-8.
34. Hommel KA, Greenley RN, Maddux MH, et al. Self-management in pediatric inflammatory bowel disease: a clinical report of the North American Society for Pediatric Gastroenterology, Hepatology, and Nutrition. J Pediatr Gastroenterol Nutr 2013; 57: 250-7.
35. Greenley RN, Kunz JH, Walter J, et al. Practical strategies for enhancing adherence to treatment regimen in inflammatory bowel disease. Inflamm Bowel Dis 2013; 19: 1534-45.
36. Van Mierlo T, Fournier R, Ingham M. Targeting medication non-adherence behavior in selected autoimmune diseases: a systematic approach to digital health program development. PLoS One 2015; 10: e0129364.
37. Wysocki T, Harris MA, Buckloh LM, et al. Effects of behavioral family systems therapy for diabetes on adolescents' family relationships, treatment adherence, and metabolic control. J Pediatr Psychol 2006; 31: 928-38.
38. Ellis DA, Podolski C-L, Frey M, et al. The role of parental monitoring in adolescent health outcomes: impact on regimen adherence in youth with type 1 diabetes. J Pediatr Psychol 2007; 32: 907-17.
39. Ross SC, Strachan J, Russell RK, et al. Psychosocial functioning and health-related quality of life in paediatric inflammatory bowel disease. J Pediatr Gastroenterol Nutr 2011; 53: 480-8.
40. Kane S, Huo D, Aikens J, et al. Medication nonadherence and the outcomes of patients with quiescent ulcerative colitis. Am J Med 2003; 114: 39-43.
41. Higgins PDR, Rubin DT, Kaulback K, et al. Systematic review: impact of non-adherence to 5-aminosalicylic acid products on the frequency and cost of ulcerative colitis flares. Aliment Pharmacol Ther 2009; 29: 247-57.
42. Egger M, Zellweger-Zähner T, Schneider M, et al. Language bias in randomised controlled trials published in English and German. Lancet 1997; 350: 326-9.
43. Morrison A, Polisena J, Husereau D, et al. The effect of Englishlanguage restriction on systematic review-based meta-analyses: a systematic review of empirical studies. Int J Technol Assess Health Care 2012; 28: 138-44.
44. Hommel KA, Mackner LM, Denson LA, et al. Treatment regimen adherence in pediatric gastroenterology. J Pediatr Gastroenterol Nutr 2008; 47: 526-43.